Existing data sources for clinical epidemiology: The western Denmark heart registry

Clinical Epidemiology

Volumn 2, Issue 1, 2010, Pages 137-144

  Schmidt, Morten ^a   Maeng, Michael ^a   Jakobsen, Carl Johan ^a   Madsen, Morten ^a   Thuesen, Leif ^a   Hostrup Nielsen, Per ^a   Erik Bøtker, Hans ^a   Toft Sørensen, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiac surgical procedures; Catheterization; Coronary angiography; Database; Epidemiology; Registries

Indexed keywords

EID: 78650956516     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/clep.s10190     Document Type: Review

References (28)

1. The Danish National Board of Health. Future need for revascularization treatment of ischemic heart disease - including PCI treatment (Heart Plan 2003) 2003.
2. Abildstrøm SZ, Kruse M, Rasmussen S, et al. The Danish Heart Registry-a clinical database. Ugeskr laeger. 2008;170(7):532-536.
3. www.hjerteregister.dk
4. Frank L. Epidemiology: when an entire country is a cohort. Science. 2000;287(5462):2398-2399.
5. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441-449.
6. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46(4):354-357.
7. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268.
8. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967-1974.
9. Christiansen JU, Maruard CD, Nielsen HC. LABKA. A real-time computer system for the clinical laboratory. Scand J Clin Lab Invest Suppl. 1989;194:57-61.
10. The board of Western Denmak Heart Registry. Western Denmark Heart Registry. Annual Report 2008 (Data from 2007 and 2008) 2009.
11. Brook RH, McGlynn EA, Cleary PD. Quality of health care. Part 2: measuring quality of care. N Eng J Med. 1996;335(13):966-970.
12. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care. 2003;15(6):523-530.
13. Sorensen HT, Sabroe S, Olsen J. A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol. 1996;25(2):435-442.
14. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007;50(5):463-470.
15. Jensen LO, Kaltoft A, Thayssen P, et al. Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention. Catheter Cardiovasc Interv. 2009;75(1):101-108.
16. Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol. 2009;53(8):658-664.
17. Maeng M, Jensen LO, Rasmussen K, et al. Target lesion revascularization in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. Heart. 2007;93(6):694-697.
18. Schmidt M, Maeng M, Pedersen L, Lassen JF, Nielsen TT, Sørensen HT. Do selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs increase the risk of cardiovascular events and death after intracoronary stenting? [Abstract]. Pharmacoepidemiol Drug Saf. 2009;18 Suppl 1:113.
19. Jensen LO, Maeng M, Thayssen P, et al. Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction. Circulation Cardiovasc Interv. 2008;1(3):176-184.
20. Maeng M, Jensen LO, Kaltoft A, et al. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus. Am J Cardiol. 2008;102(2):165-172.
21. Mortensen KH, Thuesen L, Kristensen IB, Christiansen EH. Spontaneous coronary artery dissection: a Western Denmark Heart Registry study. Catheter Cardiovasc Interv. 2009;74(5):710-717.
22. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-2913.
23. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation: Cardiovascular Quality and Outcomes. 2009;2(3):155-163.
24. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth. 2007;21(5):664-671.
25. Jakobsen CJ, Søndergaard F, Hjortdal VE, Johnsen SP. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study. Eur J Cardiothorac Surg. 2009;36(5):863-868.
26. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988;78(2):486-502.
27. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990; 82(4):1193-1202.
28. Nashef SA, Roques F, Hammill BG, et al. Validation of european system for cardiac operative risk evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg. 2002;22(1):101-105.